Research
Hormonal
Tirzepatide shows promise for treating Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) by reducing liver fat content and improving liver enzymes, likely through indirect weight loss and metabolic effects.
For diabetics with fatty liver, Tirzepatide may help reduce liver fat and improve liver enzymes, likely by aiding weight loss and metabolic health. However, more specific clinical trials are needed to confirm its efficacy as a primary treatment for NASH.
ModerateConditionalMEDIUM confidence
tirzepatide was found to lower liver fat content considerably compared to insulin... high doses of the dual GIP/GLP-RA agonist, tirzepatide, significantly improved K-18, Pro-C3, and lipocalin compared to placebo
Why this rating
Based on post-hoc analyses and substudies; definitive RCTs (NCT04166773) were ongoing.
Source
Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
Zijun Ma et al. · Journal of Diabetes Research · 2023
DOI 10.1155/2023/5891532
narrative_reviewCited 19×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and greater weight loss compared to GLP-1 receptor agonists (semaglutide, dulaglutide) and insulin analogs (degludec, glargine) in patients with type 2 diabetes.Good
- Tirzepatide demonstrates potential for cardiovascular protection, including reduced risk of major adverse cardiovascular events (MACE-4) and improved lipid profiles, in patients with Type 2 Diabetes.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →